WO2026046291 - PREPARATION AND USE OF HETEROCYCLIC COMPOUND
National phase entry is expected:
Publication Number
WO/2026/046291
Publication Date
05.03.2026
International Application No.
PCT/CN2025/117539
International Filing Date
28.08.2025
Title **
[English]
PREPARATION AND USE OF HETEROCYCLIC COMPOUND
[French]
PRÉPARATION ET UTILISATION D'UN COMPOSÉ HÉTÉROCYCLIQUE
[Chinese]
杂环化合物的制备及应用
Applicants **
SHANDONG SIMCERE ZAIMING BIOPHARMACEUTICAL CO., LTD.
Inventors
JIN, Jinghai
ZHANG, Hao
ZHU, Wei
JIANG, Lei
LI, Zhengtao
Priority Data
202411200485.9
29.08.2024
CN
202411306838.3
19.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1928 | |
| EPO | Filing, Examination, Granting | 13796 | |
| Japan | Filing, Examination, Granting | 2296 | |
| South Korea | Filing, Examination, Granting | 2409 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
25,169
Contact Us
Abstract[English]
Provided are a CDK4 inhibitor compound as represented by formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug for preventing or treating CDK4-mediated diseases.[French]
L'invention concerne un composé inhibiteur de CDK4 tel que représenté par la formule (I) ou un stéréoisomère de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique le contenant, et son utilisation dans la préparation d'un médicament pour la prévention ou le traitement de maladies médiées par CDK4.[Chinese]
提供式(I)所示CDK4抑制剂化合物或其立体异构体或其药学上可接受的盐、含有它们的药物组合物、以及其在制备预防或治疗CDK4介导的疾病的药物中的用途。